Clinical Trial Update: Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity [Phase 2]

View source ↗

Summary

Phase 2 trial of AV608 for idiopathic detrusor overactivity (overactive bladder) evaluated safety and efficacy; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Detrusor Overactivity
• Overactive Bladder

Drugs mentioned

• AV608

Snippet

Sponsor: Avera Pharmaceuticals | Conditions: Overactive Bladder Syndrome | Phase 2 | Status: TERMINATED